MiniMed Group, Inc. Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Que Thanh Dallara
- Full Time Employees
- 8,000
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- Address
- 18000 Devonshire Street Northridge CA United States of America 91325
- IPO Date
- Mar 5, 2026
- CIK
- 0002062583
- Website
- minimed.com
- Similar Companies
- Business
- MiniMed Group, Inc. (MMED) is a medical technology company focused on diabetes management solutions. The company develops, manufactures, and markets advanced insulin pumps, continuous glucose monitoring (CGM) systems, and related diabetes care products, including the MiniMed Paradigm insulin pump system; the Guardian CGM sensors and transmitters; integrated sensor-augmented pump therapy; and software platforms for data analysis and remote monitoring. It serves patients, healthcare providers, and distributors primarily in North America, Europe, and select Asia-Pacific markets. Founded in 1983 and headquartered in Northridge, California, MiniMed pioneered external insulin infusion pumps and expanded into sensor technology through key innovations in the 1990s and 2000s. In recent years, the company has pursued strategic growth, including a 2024 partnership with a leading digital health platform to enhance app-based diabetes management integration and a 2025 Series B funding round exceeding $150 million to accelerate next-generation CGM development. Additionally, MiniMed launched its MiniMed 870G system with automated insulin delivery in late 2025, marking a significant advancement in closed-loop therapy, while expanding operations into Latin America through a new distribution alliance.
MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries
MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
MiniMed Launches Abbott's Instinct Sensors Across European Markets
MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes
MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.
MiniMed Group Q4 Earnings Call Highlights
MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook
MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions
MiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm
New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
MiniMed Aims to Be 'Self-Driving Car' of Diabetes Care
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
MiniMed announces Health Canada License for Simplera Sync™ Sensor, Type 2 Diabetes Indication with MiniMed™ 780G System
Head-To-Head Review: MiniMed Group (NASDAQ:MMED) & Biosig Technologies (NASDAQ:STEX)
Head-To-Head Survey: MiniMed Group (NASDAQ:MMED) versus Longevity Health (NASDAQ:XAGE)
MiniMed to announce financial results for its fourth quarter and full fiscal year 2026